Clinical trials Below are current clinical trials.120 studies in Neurology (open studies only). Filter this list of studies by location, status and more. A Study to Evaluate Newly-diagnosed Idiopathic Generalized Epilepsy Rochester, Minn. The purpose of this study is to identify clinical characteristics and biomarkers predictive of disease outcome, progression, and treatment response in participants with idiopathic generalized epilepsy (IGE). Posterior Fossa Decompression with or without Duraplasty for Chiari Type I Malformation with Syringomyelia Rochester, Minn. The purpose of this study is to determine whether a posterior fossa decompression or a posterior fossa decompression with duraplasty results in better patient outcomes with fewer complications and improved quality of life in those who have Chiari malformation type I and syringomyelia. A Study of Mood Symptoms in Epilepsy Patients Rochester, Minn. The purpose of this study is to track neuropsychiatric symptoms in patients with epilepsy. Natural History Study Protocol in PMM2-CDG (CDG-Ia) Rochester, Minn. Clinical and Basic Investigations into Phosphomannomutase deficiency (PMM2-CDG) This is a natural history (observational) protocol designed to collect clinical and biological information in patients with PMM2-CDG (CDG-Ia). Data from this natural history study will be used to determine a set of clinical and biological parameters that will be used for primary and secondary endpoints in a later clinical trial with a new chemical entity, Lipo-M1P. Ado-trastuzumab emtansine (T-DM1)-Induced Peripheral Neuropathy in HER2-positive Breast Cancer Patients Rochester, Minn. The purpose of this study is to prospectively evaluate the patient-reported outcomes data of T-DM1 induced peripheral neuropathy like prior research focused on paclitaxel-, paclitaxel/CBDCA-, oxaliplatin-, and cisplatin-induced peripheral neuropathy, to better understand the similarities and differences of chemotherapy-induced peripheral neuropathy (CIPN) symptoms caused by different agents, their pathogenesis, and impacts. The Neurobiology of Two Distinct Types of Progressive Apraxia of Speech Rochester, Minn. The purpose of this study is to identify and distinguish two different types of Progressive Apraxia of Speech through clinical imaging and testing. A Study to Evaluate Caregiver Connections via Technology for Patients with Alzheimer's and Other Types of Dementia Rochester, Minn. The purpose of this study is to optimize profile questionnaire and matching algorithm developed in Phase I and implement in final website design, and to determine if algorithmically matched participants have statistically significant increase in match satisfaction and self-reported sense of resiliency and quality of life over randomly matched caregivers. A Study to Evaluate Traditional Versus Early Aggressive Therapy for Multiple Sclerosis Patients Rochester, Minn. The purpose of this study is to evaluate, jointly and independently among patients deemed at higher risk vs. lower risk for disability accumulation, whether an "early aggressive" therapy approach, versus starting with a traditional, first-line therapy, influences the intermediate-term risk of disability, and to evaluate if, among patients deemed at lower risk for disability who start on first-line MS therapies but experience breakthrough disease, those who switch to a higher-efficacy versus a new first-line therapy have different intermediate-term risk of disability.FDA-approved multiple sclerosis (MS) disease-modifying therapies (DMTs) target the relapsing phase of MS but have minimal impact once the progressive phase has begun. It is unclear if, in the relapsing phase, there is an advantage of early aggressive therapy with respect to preventing long-term disability. The infectious risks and other complications associated with higher-efficacy treatments highlight the need to quantify their effectiveness in preventing disability. The TRaditional versus Early Aggressive Therapy for MS (TREAT-MS) trial is a pragmatic, randomized controlled trial that has two primary aims: HEALEY ALS Platform Trial Rochester, Minn., Jacksonville, Fla., Scottsdale/Phoenix, Ariz. The purpose of this study is to evaluate the safety and effectiveness of investigational products for the treatment of ALS. Reduced Craniospinal Radiation Therapy and Chemotherapy in Treating Younger Patients With Newly Diagnosed WNT-Driven Medulloblastoma Rochester, Minn. This phase II trial studies how well reduced doses of radiation therapy to the brain and spine (craniospinal) and chemotherapy work in treating patients with newly diagnosed type of brain tumor called WNT)/Wingless (WNT)-driven medulloblastoma. Recent studies using chemotherapy and radiation therapy have been shown to be effective in treating patients with WNT-driven medulloblastoma. However, there is a concern about the late side effects of treatment, such as learning difficulties, lower amounts of hormones, or other problems in performing daily activities. Radiotherapy uses high-energy radiation from x-rays to kill cancer cells and shrink tumors. Drugs used in chemotherapy, such as cisplatin, vincristine sulfate, cyclophosphamide and lomustine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving reduced craniospinal radiation therapy and chemotherapy may kill tumor cells and may also reduce the late side effects of treatment. Pagination Clinical studies Go to page 11 Go to page 22 Go to page 33 Go to page 44 Go to page 55 NextNext Page Request an appointment Expertise & rankingsResearch June 19, 2024 Share on: FacebookTwitter Mayo Clinic in Rochester, Minnesota, Mayo Clinic in Phoenix/Scottsdale, Arizona, and Mayo Clinic in Jacksonville, Florida, have been ranked among the best Neurology & Neurosurgery hospitals in the nation for 2024-2025 by U.S. News & World Report. Learn more about this top honor NeurologyDepartmenthomeSectionsOverviewTests & proceduresConditions treatedDoctorsSpecialty groupsExpertise & rankingsClinical trialsResearchPatient storiesCosts & insuranceNews from Mayo ClinicReferrals Research: It's all about patients Show transcript for video Research: It's all about patients [MUSIC PLAYING] Joseph Sirven, M.D., Professor of Neurology, Mayo Clinic: Mayo's mission is about the patient. The patient comes first. So the mission and research here is to advance how we can best help the patient, how to make sure the patient comes first in care. So in many ways, it's a cycle. It can start with as simple as an idea worked on in a laboratory, brought to the patient bedside, and if everything goes right — and let's say it's helpful or beneficial — then brought on as a standard approach. And I think that is one of the unique characteristics of Mayo's approach to research — that patient-centeredness — that really helps to put it in its own spotlight. SectionsRequest an AppointmentOverviewTests & proceduresConditions treatedDoctorsSpecialty groupsExpertise & rankingsClinical trialsResearchPatient storiesCosts & insuranceNews from Mayo ClinicReferrals ORG-20117054 Medical Departments & Centers Neurology